Lumipulse® G 25-OH Vitamin D
New "ray of light" in Vitamin D testing
Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency.
Product number 235089
Product number 234020
Click here to navigate
- Conditions of sale
- Related products
- Product inquiry
Advantages & Features
- Sandwich assay - showing improved performance
- Improved equimolarity - 25-OH Vitamin D2 and D3
- Higher correlation with LC-MS/MS
- A broad dynamic assay range - 4,0-150 ng/mL
- Novel VDBP release, no manual steps or auxilliary reagents required
- Good precision - within run 0,7-2,2% and total precision 1,6-3,5%
- 25 minute assay time, with a real throughput of 120 tests/hour combined with other analytes
- 30 day calibration
- Individual cartridge concept
Vitamin D is a fat-soluble, secosteroid hormone precursor. In humans, the most abundant forms are Vitamin D3 (cholecalciferol), followed by Vitamin D2 (ergocalciferol), known together as calciferol. Calciferol primarily undergoes hydroxylation in the liver to 25-OH Vitamin D (calcidiol), the major circulating form of vitamin D. The serum or plasma level of 25-OH Vitamin D is recognized as the most reliable indicator of vitamin D sufficiency. A second hydroxylation in the kidneys of a small amount of 25-OH Vitamin D produces 1,25(OH)2 Vitamin D (calcitriol). Calcitriol regulates calcium and phosphate blood concentrations through amongst other intestinal absorption.
Did you know?
Low 25-OH Vitamin D serum levels (lower than 10 ng/ml) have been found in 2-30% of adults within the European population 
Vitamin D deficiency was first discovered in the childhood disease rickets. However due to recent trends to avoid prolonged sun exposure due to cancer and aging impacts, the world's population is even more at risk. Deficiency has been linked to various other medical conditions other than bone metabolism such as: adult osteomalacia, incresed risk for fractures, secondary hyperparathyroidism, autoimmune diseases, diabetes, associated with increased risk for certain cancers, and cardiovascular problems.
International Osteroporosis Foundation.
WHO Scientific Group on the Prevention and Management of Osteoporosis 2003 Prevention and management of osteoporosis: report of a WHO scientific group. Geneva: World Health Organization.
Holick MF et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab. 2011; 96: 1911-1930.
See the LUMIPULSE G1200 working in this video:
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
Other documentsFilePoster_Wielders_NVKC_Voorjaarscongres_2015.pdf (pdf, 230.55 kb)FileLumipulse G 25-OH Vitamin D product leaflet.pdf (pdf, 1.19 mb)FileDEQAS certification.pdf (pdf, 69.46 kb)FileCDC Certified Vitamin D Procedures Sept2016 changed.pdf (pdf, 311.19 kb)FileL54 VDSCP Certificate 120816.pdf (pdf, 4.47 mb)
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
Vitamin D Control
Product number 2130152 -
Assayed, tri-level control containing both 25(OH) Vitamin D2 and 25(OH) Vitamin D3.CE marked
Lumipulse® G whole PTH
Product number 297094 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of whole (1-84) PTH in human serum or plasma based on CLEIA technology by a one-step sandwich immunoassay method on the LUMIPULSE G System with results that are available in up to 35 minutes.CE marked
Product number 232002 -
A robust, mid-sized and fully automated chemiluminescent enzyme immunoassay (CLEIA) system from the already widely successful LUMIPULSE series.CE marked